Item 3. Legal Proceedings
Item 3. Legal Proceedings
From time
to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We
are currently not a party to any material legal or administrative proceedings, and we are not aware of any pending or threatened material
legal or administrative proceedings against us.
Item 4. Mine Safety Disclosures
Not applicable.
Item 4.1 Information About Our Executive Officers
The following information sets forth the names,
ages, and positions of our executive officers as of March 20, 2025.
Name
Age
Positions and Offices Held
Stephen L. Silvestro
47
Chief Executive Officer
Marion Odence-Ford
60
General Legal Officer and Chief Human Resources Officer
Edward Stelmakh
59
Chief Financial Officer and Chief Operations Officer
Doug Besch
43
Chief Product Officer and Chief Technology Officer
Theresa Greco
52
Chief Commercial Officer
Set forth below is a brief description of
the background and business experience of each of our current executive officers.
Stephen L. Silvestro
Mr. Silvestro was appointed the Chief Executive
Officer in March 2025. He joined the Company as Chief Commercial Officer in April 2019 and has since served as President from October
2023 until his appointment as interim CEO in January 2025. Prior to joining the Company, Mr. Silvestro was with CCH® Tagetik, a Wolters
Kluwer company that provides corporate performance management software solutions for planning, consolidation and reporting, as its Vice
President and General Manager from January 2018 until April 2019. From April 2017 to January 2018, Mr. Silvestro was with Prognos Health,
Inc., a healthcare data and analytics company, as its Chief Commercial Officer and, before that, from September 2007 to April 2017, he
was with Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics and consulting
services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in various capacities
with him last serving as Executive Vice President, Head of Global Sales.
20
Marion Odence-Ford
Ms. Odence-Ford was named the Chief Legal Officer
and Chief Human Resources Officer effective January 1, 2025. She joined the Company as General Counsel & Chief Compliance Officer
in February 2021. From April 2013 to June 2020, Ms. Odence-Ford was Vice President & Deputy General Counsel at Decision Resources
Group, a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical,
biotech, medical device, healthcare provider and payer, and managed care companies. From November 2004 to November 2012, Ms. Odence-Ford
was Vice President & Associate General Counsel at CRA International, Inc. (dba Charles River Associates), a global consulting firm
that offers economic, financial, and strategic expertise to major law firms, corporations, accounting firms, and governments around the
world. From May 2004 to November 2004, Ms. Odence-Ford was a member of the GTC Law Group, LLP, a law firm specializing in the business
affairs of companies in the high tech and biotech industries. Prior to joining the GTC Law Group, Ms. Odence-Ford worked on the legal
teams of Bank of America Corporation/Fleet Boston Financial Corporation from November 2002 to May 2004, and Akamai Technologies, Inc.
from October 1999 to November 2002. Ms. Odence-Ford began her legal career in private practice at Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, PC, where she advised public and private companies on corporate matters.
Edward Stelmakh
Mr. Stelmakh joined the Company as Chief Financial
Officer and Chief Operating Officer in October 2021. Prior to joining the Company, Mr. Stelmakh served as Senior Vice President, Chief
Financial Officer and Chief Operating Officer of Otsuka America Pharmaceuticals Inc. (“Otsuka”), a US division of a Japanese
global healthcare enterprise, since April 2020. Previously, he held various positions at Otsuka including Senior Vice President and Chief
Financial Officer (December 2017 – March 2020) and Vice President and Chief Financial Officer (December 2015 – November 2017).
From March 2010 to December 2015, Mr. Stelmakh worked at Covance, a division of LabCorp, Inc., as Vice President, Finance, Clinical Development
and Commercialization Services. Prior thereto, Mr. Stelmakh held a variety of positions of increasing responsibilities at Johnson &
Johnson, Sanofi-Aventis, Organon/Schering-Plough and Mylan.
Doug Besch
Dr. Besch was named the Chief Product Officer
and Chief Technology Officer effective January 1, 2025. He joined the Company in May 2021 as SVP Product Strategy & Innovation and
became the Company’s Chief Product Officer in October 2022. Prior to joining the Company, from January 2018 to May 2021, Dr. Besch was
the Vice President over Payor and Market Access Solutions for Clarivate (previously Decision Resources Group (DRG)), a multi-national
corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device,
healthcare provider and payer, and managed care companies. Prior to Clarivate, from January 2012 to June 2017, Dr. Besch was a co-founder
and the Chief Product Officer for Rx Savings Solution, a company which helps members and payers
reduce prescription drug costs through a combination of clinical technology, transparency, member engagement and concierge support .
Dr. Besch holds a PharmD and MBA from Creighton University and practiced as a pharmacist for the Walgreens Boots Alliance corporation
from 2007 through 2013.
Theresa Greco
Ms. Greco joined the Company in October 2023 as
the Company’s Chief Commercial Officer with the Company’s acquisition of Healthy Offers, Inc. (“Medicx Health”),
where Ms. Greco served as its President since August 2022. Prior to joining Medicx Health, Ms. Greco was at Prognos Health, Inc., a healthcare
data and analytics company, from August 2018 to January 2022 as its Chief Commercial Officer where she led all aspects of product strategy,
marketing, sales, and customer delivery. Prior to Prognos, Ms. Greco held the Chief Commercial Officer position at MediSpend, a global
technology company focused on life sciences compliance solutions. From August 2010 through August 2017, Ms. Greco was with LexisNexis
Healthcare through their acquisition of Health Market Science, where she held a variety of progressive executive positions including in
Customer Success, Product Strategy, Commercial Strategy, and Sales that contributed to revenue growth and profitability that yielded a
successful exit. Ms. Greco led the Life Sciences consulting group providing consultation and technology solutions to life sciences companies
for master data management at Computer Sciences Corporation from April 2008 to August 2010. Prior to 2008, Ms. Greco held various positions
at IQVIA and Pfizer.
21
PART II